Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Polycystic Ovary Syndrome 2Insulin Resistance 1

Interventions

Inositol 6follitropin alfa 4Glycoprotein Hormones, alpha Subunit 3follitropin beta 2Metformin 2Letrozole 2DLBS3233 2Clomiphene 2Chorionic Gonadotropin 2licogliflozin 1elagolix 1cetrorelix 1Urofollitropin 1Secretome 1Progesterone 1Oils 1Menotropins 1Leuprolide 1Lactalbumin 1LHRH, Ac-Nal(1)-Cpa(2)-Trp(3)-Arg(6)-Ala(10)- 1Itraconazole 1Folic Acid 1Diosgenin 1Contraceptives, Oral 1Cholecalciferol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Polycystic Ovary Syndrome × DLBS3233 × Clear all
NCT01999686 2019-05-28

POSITIF

Dexa Medica Group

Phase 3 Completed
186 enrolled

Insulin Resistance, Polycystic Ovary Syndrome

NCT01733459 2018-07-26

Efficacy and Safety of DLBS3233 in Subjects With Polycystic Ovary Syndrome (PCOS)

Dexa Medica Group

Phase 3 Completed
124 enrolled

Polycystic Ovary Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡